TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01188486

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Standard of care diagnostic radiotherapy procedure

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: For each participant, 3 chest CT scans will be obtained, 1 before and 2 after interstitial injection of the water-soluble contrast

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyberknife
Description: Linear accelerator for producing high energy x-rays for radiation therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trilogy
Description: Linear accelerator for producing high energy x-rays for radiation therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: True Beam
Description: Linear accelerator for producing high energy x-rays for radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iohexol
Description: Aqueous solution of a nonionic, water-soluble radiographic contrast medium in prefilled cartridges with a molecular weight of 821.14 (iodine content 46.36%), available at 140, 180, 240, 300, and 350 mgI/mL.
Study: NCT04811378

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HaemoCer
Description: Randomized application of 3g haemostatic powder (HaemoCer) in the wound site during breast-conserving surgery.
Study: NCT00434954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide twice daily (BID)
Description: subcutaneous injection (5 mcg or 10 mcg), twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: premixed insulin aspart twice daily (BID)
Description: subcutaneous injection (titrated appropriately), twice a day
Study: NCT01175460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1, Nedaplatin
Description: nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 on Days 1-14, repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
Study: NCT00002651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin acetate
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Description: Given subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical observation
Description: Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.
Study: NCT03935841

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3-OHB salt (NaCl)
Description: 36 gram 3-OHB salt diluted in 500 ml sterile water
Study: NCT04439110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Given IV
Study: NCT01649050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGG492

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01787422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional versus Telemedicine office visit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional versus Telemedicine office visit
Study: NCT00400738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saquinavir, lopinavir, ritonavir
Description: arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID
Study: NCT01188486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodixanol
Description: Aqueous solution of a nonionic, water-soluble, dimeric, isosmolar, radiographic contrast medium with a molecular weight of 1550.20 (iodine content 49.1%), available in 2 concentrations, (270 mgI/mL and 320 mgI/mL.
Study: NCT01429779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Movicol
Description: Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
Study: NCT01813903

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensified dietary counseling
Description: The intervention is completed by public health nurses who will be trained to provide family-centered empowering and motivational lifestyle counseling at the normal health check visit. Parents expecting child will use web application developed for nutritional counseling. Web application consists of dietary questionnaire from which the parents will receive immediately automatic feedback. Feedback concerns the quality of diet in relation to the Finnish nutrition recommendations. Feedback will be given in an encouraging format. Own targets of food changes can also be recorded in the application, and the application can be used to monitor how they are achieved.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile application
Description: Mothers expecting child will use mobile application. Mobile application consists of text, audio and video exercises, which are aimed to increase the psychological flexibility and thus mental and physical well-being.
Study: NCT03035656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Administration of Ropivaciane via epidural injection intra-operatively

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Administration of saline via epidural injection intra-operatively
Study: NCT04358328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) and care
Description: Comprehensive geriatric assessment and care including geriatric-, nursing-, physiotherapist-, and dietician assessments followed by appropriate interventions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard pre-, peri- and post operative care.
Study: NCT03795701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxenda®
Description: Receiving escalating dose of Saxenda® for the first 4 weeks (0.6mg, 1.2mg, 1.8mg, 2.4 mg) and receiving full-dose (3.0 mg) for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Receiving equivalent volumes of the pre-filled solutions from pen-injector as Liraglutide 3.0 group .
Study: NCT03646331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin Reference product
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin Reference product
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin
Description: Test product (new formulation tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin
Description: Test product (new formulation tablet)
Study: NCT01710514

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FE 999913 vaginal tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FE 999913 vaginal tablet
Study: NCT04675463

Intervention type: DRUG
Group type: OTHER
Intervention: BGF Inhalation Aerosphere
Description: Budesonide/Glycopyrronium/Formoterol: 160/7.2/4.8/ puff, twice daily with two puffs per time

Intervention type: DRUG
Group type: OTHER
Intervention: GFF Inhalation Aerosphere
Description: Glycopyrronium/Formoterol: 7.2/4.8 per puff, twice daily with two puffs per time
Study: NCT04044664

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-783
Description: NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-783
Description: NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
Study: NCT02648529

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: Patients are investigated with the following sequences:~* High-resolution 3D T1-weighted anatomical MRI.~* DTI with 48 directions (to examine white matter)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Patients are investigated with the following sequences:~* High-resolution 3D T1-weighted anatomical MRI.~* DTI with 48 directions (to examine white matter)
Study: NCT02648529

Intervention type: PROCEDURE
Group type: OTHER
Intervention: functional MRI (fMRI)
Description: fMRI investigations will be focused on :~* language: investigation on possible atypical language networks in children with epilepsy. The fMRI task is a silent verb generation.~* Social cognition: investigations on social cognition skills~* Memory :~* Declarative memory: investigations on the pattern of activations in the brain associated with successful memory formation and changes from childhood to adolescence~* Working memory: A verbal and a spatial working memory task has been chosen, and is an adaptation of two published cross-sectional studies of working memory from Gabrieli and Sowell groups.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: functional MRI (fMRI)
Description: fMRI investigations will be focused on :~* language: investigation on possible atypical language networks in children with epilepsy. The fMRI task is a silent verb generation.~* Social cognition: investigations on social cognition skills~* Memory :~* Declarative memory: investigations on the pattern of activations in the brain associated with successful memory formation and changes from childhood to adolescence~* Working memory: A verbal and a spatial working memory task has been chosen, and is an adaptation of two published cross-sectional studies of working memory from Gabrieli and Sowell groups.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: neuropsychological assessment
Description: Patients undergo a repeated annual neuropsychological assessment over the five years of their participation in the project.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: neuropsychological assessment
Description: Patients undergo a repeated annual neuropsychological assessment over the five years of their participation in the project.
Study: NCT03163862

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Endometrial scratch
Description: the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial scratch
Description: the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF administration
Description: 1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, subcutaneous 300 micrograms G-CSF on the day of embryo transfer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: saline infusion every day from the day of embryo transfer through the day of beta HCG test
Study: NCT04146818

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Tango Dancing
Description: Treatment will include sessions of Adapted Tango (90 min per week for a total of 6 months) together with sessions of comprehensive cognitive intervention (90 min per week for a total of 6 months) consisting in music therapy, engagement in social activities, cognitive training and psycho-education.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Sessions of psycho-education and advice on healthy life-style (once per month for a total of 6 months)
Study: NCT02974010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-101 Oral Capsule
Description: Prospective Randomized Factorial Design Study as per arm/group descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lurasidone Oral Capsule
Description: Prospective Randomized Factorial Design Study as per arm/group descriptions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Intravenous Infusion
Description: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Intravenous Infusion
Description: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution Intravenous Infusion
Description: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution Intravenous Infusion
Description: Randomized administration of Ketamine or Placebo in a 3 to 1 ratio
Study: NCT02805244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTZ-951, 14C-JTZ-951
Study: NCT04590989

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Nutrition Plan
Description: * Personalized breakfasts and dinners designed and cooked by Simplefeast, delivered twice a week (eaten 6 days per week) + access to Simplefeast's App for recipes of other meals not provided (i.e. lunches and Saturdays) which are designed to match the individual nutritional recommendations.~* Personalized behavioral change program via electronic push notifications by ONMI

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-Personalized Nutrition Plan
Description: * Standard meals of breakfasts and dinners designed and cooked by Simple feast, based on general dietary recommendations, and delivered to participants twice a week. In addition, they will also have access to Simple feast's recipe App for other meals not provided. The recipes presented are generic, not personalized.~* Subjects in the control group will also be enrolled in the behavioral program by ONMI, but the program will not be personalized nor based on the same behavior change methodology as in the PP group. In other words, the control group will get information more than is triggered to take actual action (i.e. general guidelines that is available from the National Health Service and World Health Organization).
Study: NCT00647205

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: QuantiFERON TB Gold In-Tube
Study: NCT02421016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY EES
Description: Bioresorbable polymer everolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ABSORB [BVS]
Description: Everolimus-eluting bioresorbable backbone stent
Study: NCT00792441

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: intervention group
Description: inspiratory muscle training at 50% of peak negative inspiratory muscle training (PNIP)will be performed with 6 breathe/set, 10 set/day, once a day for 28 days.
Study: NCT04347330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive BP Control
Description: Participants in the Intensive group have a goal of home SBP \<120 mm Hg. The CRAFT BP treatment protocol is flexible in terms of the choice and doses of antihypertensive medications, but there should be preferences among the drug classes, based on CVD outcome trials results and current guidelines. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. Combination of different classes of agents are encouraged to achieve the home SBP goal. Medications will not be provided by the CRAFT study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard BP Control
Description: Participants in the Standard group has a goal of home SBP \<135 mmHg. The same principle of BP treatment in the Intensive BP arm will be used for the Standard BP arm. Medications will not be provided by the CRAFT study.
Study: NCT01417351

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 400 IU vitamin D3
Description: Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 2,000 IU Vitamin D3
Description: Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
Study: NCT03398590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-regulation theory-based mHealth behavior intervention
Description: Participants will receive a self-regulation theory-based mHealth behavior intervention (5 biweekly group sessions, 60 minutes /session). An experienced Certified Diabetes Educator from the Joslin Diabetes Center and PI (Dr. Zheng) who has been trained using self-regulation for weight loss will co-facilitate group sessions. The intervention combines diet modification and increased physical activity with a weekly weight loss goal as well as focuses on improving participants' three typical self-regulation strategies - self-monitoring, self-evaluation and self-reinforcement. Intervention duration will last 2 months with subsequent 1-month follow.
Study: NCT01540292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSC)
Description: MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart
Study: NCT00736398

Intervention type: PROCEDURE
Intervention: Spinal fusion
Description: Spinal fusion
Study: NCT02625506

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine
Description: Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine and Tramadol
Description: Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
Study: NCT03319069

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Hypofractionated radiotherapy 43,5 GY/15 fractions (f)/3ws. to chest wall and supraclavicular nodal region.~.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional fractionated radiotherapy
Description: 50 Gray(GY)/ 25f/5 weeks(5w) to chest wall and supraclavicular nodal region
Study: NCT02426541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
Study: NCT02031237

Intervention type: RADIATION
Intervention: Single Fraction Stereotactic Radiosurgery (SRS)
Description: Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.

Intervention type: RADIATION
Intervention: Fractionated Whole Brain Radiation Therapy (WBRT)
Description: Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.

Intervention type: RADIATION
Intervention: Fractionated Stereotactic Radiation Therapy (FSRT)
Description: Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI) Assessments
Description: MRI scans will include a routine clinical MRI series.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI) Assessments
Description: MRI scans will include a routine clinical MRI series.

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging (MRI) Assessments
Description: MRI scans will include a routine clinical MRI series.
Study: NCT02317250

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amyloid imaging
Description: Amyloid imaging brain scans are administered once to all arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amyloid imaging
Description: Amyloid imaging brain scans are administered once to all arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amyloid imaging
Description: Amyloid imaging brain scans are administered once to all arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amyloid imaging
Description: Amyloid imaging brain scans are administered once to all arms.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDG-PET
Description: \[F-18\] FDG-PET brain scans are administered once to all arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: \[F-18\] FDG-PET brain scans are administered once to all arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: \[F-18\] FDG-PET brain scans are administered once to all arms.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: \[F-18\] FDG-PET brain scans are administered once to all arms.
Study: NCT04847999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Description: Dark chocolate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dark chocolate
Description: Dark chocolate
Study: NCT01110317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone palmitate 100 mg
Description: Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1, 8, 36, and 64.
Study: NCT02145624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Repevax
Description: vaccine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix-IPV
Description: vaccine
Study: NCT02851732

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality Improvement Intervention
Description: The quality improvement intervention includes case management, reminders, check lists, educational materials, and audit and feedback reports